Eimear O’Leary
Director of Communications & Advocacy, IPHA
As Ireland prepares to assume the Presidency of the Council of the European Union, the country stands at a pivotal moment for shaping the future of its life sciences sector.
The Irish Pharmaceutical Healthcare Association (IPHA), representing the international research‑based industry in Ireland, is calling for a cohesive national Life Sciences Strategy that focuses on innovation, competitiveness and most importantly, patient access.
Ireland’s life sciences ecosystem is one of the strongest globally, but its continued success depends on the country’s ability to evolve and adapt. A rapidly changing global landscape — underscored by intensifying international competition, geopolitical uncertainty and an ageing population — demands a more strategic, future‑focused approach.
Wider impact of Ireland’s life sciences sector
Last year, the EU published its Life Sciences Vision, which Ireland needs to align with. It outlined three strategic pillars: optimising research and innovation, enabling rapid market access and boosting trust through digital uptake.
Central to Ireland’s opportunity is the strength of the life sciences industry and its role in the economy. It’s a major employer, a driver of regional development and an anchor of high‑value investment.
A thriving manufacturing base spans the country, powering exports and supporting thousands of skilled jobs. Manufacturing alone is no longer enough. To remain competitive, Ireland must build a closed‑loop life sciences ecosystem — one in which research, regulation and healthcare delivery are seamlessly connected, allowing new technologies to be tested, adopted and scaled rapidly.
Manufacturing alone is no longer enough. To remain competitive, Ireland must build a closed‑loop life sciences ecosystem — one in which research, regulation and healthcare delivery are seamlessly connected
How policy reforms can drive growth
IPHA’s vision for the National Life Sciences Strategy reflects an ecosystem that’s future‑ready, where the pricing and reimbursement system values scientific advancement, and where Ireland becomes an early‑launch market for breakthrough treatments and digital health solutions. The newly agreed IPHA Framework Agreement is a significant step, with the potential to deliver faster access to medicines and create the agility needed to respond to the next wave of medical technologies.
Today, the innovation gap between Europe and global leaders — highlighted in the Draghi Report — underscores the urgency of reform. The EU’s policy and legislative framework remains a major determinant of national competitiveness. With multiple policy files affecting the sector, Ireland must adopt a more coordinated, cross‑government approach — supported by a proposed Life Sciences Council — to ensure coherence and impact.
Ireland has the talent, infrastructure and industrial strength to lead in this era of transformative healthcare innovation. What it now requires is a unified strategy — spanning research labs to patient bedsides — that signals, unequivocally, that Ireland intends not just to participate in the future of life sciences, but to shape it.
